Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
Biotechs including Rubius Therapeutics, which raised hundreds of millions of dollars before liquidating in 2023, and Ery…
For several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapies
The Leverkusen-based pharmaceutical and life sciences group Bayer AG is strengthening its ophthalmology pipeline with a …
激活土壤潜能：以高性能定制化腐植酸体系，破解生物刺激素配方兼容与持效瓶颈
Luca Monterisi 艾敏斯帝（IMCD）农用化学品 全球业务拓展经理 Luca.Monterisi@imcd.it 摘要 腐殖酸作为低成本投入品，在农业中用于土壤调理和提高养分，已有很长的应用历史。如今作物产能、可持…
Switzerland’s biotech sector defies tough markets with record revenue
The financing side also presented a stable picture: capital inflows rose slightly, by 2.1%, to CHF 2.6 billion. What sta…
Macrocycles: big is the new beautiful
What if synthetic large molecules could be designed to fit almost any receptor pocket imaginable? While this may sound l…
Swiss Windward Bio adds US$165m to its Chinese pipeline
Basel-based Windward Bio has raised $165 million to advance a pipeline of long-acting immunology therapies—much of it so…
Cytospire raises £61M to take gamma-delta T-cell engager into the clinic
Conventional TCEs bind CD3 on T cells to drive destruction of tumor cells. The modality has improved outcomes in blood c…
Anasac联手Fyteko将信号分子引入智利，剑指鲜果采后品质
大农化网报道： 比利时生物技术公司Fyteko专注于开发新一代植物信号解决方案。该公司近日宣布与智利领先农资企业Anasac达成新合作。Anasac拥有超过78年的市场经验。该协议涵盖NURSPRAY HC在智利的商业化，初期用于樱桃、鲜食…
UCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager push
The transaction, announced on 3 May, gives UCB a portfolio of bispecific antibodies designed to redirect T cells against…
BioOrbit: record seed round for in‑space drug manufacturing
A large share of the world’s top‑selling medicines are administered intravenously in clinical settings. This ties patien…